•Labcorp's stock performance reflects stability driven by its business diversification across routine medical testing and clinical research support for biopharma.
•MicroVision shareholders approved all five proposals at the 2026 annual meeting, including authorization for the board to implement a reverse stock split.
•Approvals also included share issuance related to convertible notes and the election of directors.
